Nephrology News, Research Articles | Kidney Disorders, Treatment Studies



Diabetes Tx Gains Fast Track Designation for Kidney Disease

The FDA has granted Fast Track designation to dapagliflozin (Farxiga; AstraZeneca) as a possible treatment to delay the progression of renal failure and prevent cardiovascular (CV) and renal death in patients with chronic kidney disease.
Next post in Anemia